Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Charlotte, NC (PRWEB) September 19, 2014 ... Certified Biobased Product Label for its Organic Cotton ... the product’s amount of renewable biobased ingredients meets or ... or intermediate materials composed in whole or in significant ... “This logo/label will allow our Organic cotton to be ...
(Date:9/19/2014)... , September 19, 2014 , ... European Society for Paediatric Endocrinology (ESPE) Meeting  ... and medical research in the field of growth  , ... Darmstadt, Germany , today announced the ... for 2014. The awards were announced during a Satellite ...
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
(Date:9/18/2014)... 18, 2014 A novel robotic system ... scanner is currently being tested as part of a ... in Boston with the aim of determining if the ... prostate cancer biopsies faster, more accurate, less costly, and ... has the potential to deliver prostate cancer therapies with ...
Breaking Biology Technology:Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... Sweden has shown that biosynthetic corneas can help regenerate and ... results, from an early phase clinical trial with 10 patients, ... Science Translational Medicine . "This study is important because ... cornea can integrate with the human eye and stimulate regeneration," ...
... Enterprise Institute (Mtech) Bioprocess Scale-Up Facility (BSF) will double ... equipment, and create a pilot plant for biofuels in College ... from the Maryland Biotechnology Center . "The ... make sure the BSF,s capabilities are available to the growing ...
... bioserie is first to market with a line ... device owners the protection they demand while using only ... use of the latest in bioplastics technology offers considerably ... of environmental toxic pollution once the cover is discarded. ...
Cached Biology Technology:Seeing the world with new eyes: Biosynthetic corneas restore vision in humans 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 3bioserie Introduces the World's First 'Made of Plants' iPhone 4 Cover 2
(Date:9/19/2014)... unveiled today by researchers from several Harvard University ... both experienced and aspiring researchers with the intellectual ... robots made from soft, flexible materials. , With ... and other advances in manufacturing technology, soft robotics ... principles drawn from conventional rigid robot design, but ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2
... painted with gold purify the air when they are ... of Technology experts have discovered. Associate Professor Zhu ... Sciences said that glaziers in medieval forges were the ... different sizes. Professor Zhu said numerous church ...
... detailed images of the body,s anatomy. Thanks to novel ... scientist Eric Ahrens, MRI can be used to visualize ... in the living body. The ability to non-invasively locate ... aid the study and treatment of cancer, inflammation, and ...
... August 20, 2008 New phase 2 data published ... investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic ... PTC124 results in statistically significant improvements in the chloride ... study was conducted at the Hadassah Hebrew University Hospital ...
Cached Biology News:Air-purifying church windows early nanotechnology 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3
... fluorescent and highly photostable FluoSpheres microspheres ... a variety of applications requiring probes ... Unfortunately, protein- and other macromolecule-labeled microspheres ... them to bind to non-target surfaces ...
Goat polyclonal to Duffy / FY / DARC...
SMVT (N-14)...
... Description: Proteinase K is a highly ... range of applications purified from the fungus T. ... carboxyl group of N-substituted hydrophobic aliphatic and aromatic ... a serine protease. Proteinase K is useful in ...
Biology Products: